These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38787767)

  • 1. Understanding Mucosal Physiology and Rationale of Formulation Design for Improved Mucosal Immunity.
    Biswas M; Nurunnabi M; Khatun Z
    ACS Appl Bio Mater; 2024 Aug; 7(8):5037-5056. PubMed ID: 38787767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal vaccine design and delivery.
    Woodrow KA; Bennett KM; Lo DD
    Annu Rev Biomed Eng; 2012; 14():17-46. PubMed ID: 22524387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.
    Corthésy B; Bioley G
    Front Immunol; 2018; 9():431. PubMed ID: 29563912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal Vaccine Delivery Using Mucoadhesive Polymer Particulate Systems.
    Cho CS; Hwang SK; Gu MJ; Kim CG; Kim SK; Ju DB; Yun CH; Kim HJ
    Tissue Eng Regen Med; 2021 Oct; 18(5):693-712. PubMed ID: 34304387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers.
    Garg NK; Mangal S; Khambete H; Tyagi RK
    Recent Pat Drug Deliv Formul; 2010 Jun; 4(2):114-28. PubMed ID: 20380624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.
    Wang SH; Thompson AL; Hickey AJ; Staats HF
    Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers.
    Mishra N; Goyal AK; Tiwari S; Paliwal R; Paliwal SR; Vaidya B; Mangal S; Gupta M; Dube D; Mehta A; Vyas SP
    Expert Opin Ther Pat; 2010 May; 20(5):661-79. PubMed ID: 20345332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal and pulmonary vaccine delivery using particulate carriers.
    Jia Y; Krishnan L; Omri A
    Expert Opin Drug Deliv; 2015 Jun; 12(6):993-1008. PubMed ID: 25952104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chitosan-based particulate systems for the delivery of mucosal vaccines against infectious diseases.
    Singh B; Maharjan S; Cho KH; Cui L; Park IK; Choi YJ; Cho CS
    Int J Biol Macromol; 2018 Apr; 110():54-64. PubMed ID: 29054527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal vaccines: recent progress in understanding the natural barriers.
    Borges O; Lebre F; Bento D; Borchard G; Junginger HE
    Pharm Res; 2010 Feb; 27(2):211-23. PubMed ID: 19953309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.
    Boyaka PN
    J Immunol; 2017 Jul; 199(1):9-16. PubMed ID: 28630108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanocarriers: a versatile approach for mucosal vaccine delivery.
    Mody N; Sharma R; Agrawal U; Vyas SP
    Ther Deliv; 2015 Feb; 6(2):231-45. PubMed ID: 25690089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The development of mucosal vaccine using bacterial function for targeting mucosal tissues].
    Suzuki H; Kondoh M; Yagi K; Kiyono H; Kunisawa J
    Yakugaku Zasshi; 2014; 134(5):629-34. PubMed ID: 24790045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues.
    Czerkinsky C; Holmgren J
    Curr Top Microbiol Immunol; 2012; 354():1-18. PubMed ID: 21053117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Development of oral vaccines].
    Matsubara A; Shimizu Y; Karamatsu K; Yasutomi Y
    Nihon Rinsho; 2008 Oct; 66(10):1873-8. PubMed ID: 18939484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.
    Lawson LB; Norton EB; Clements JD
    Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Mucoadhesive Nanoparticle-Based Delivery System in the Development of Mucosal Vaccines.
    Zhao K; Xie Y; Lin X; Xu W
    Int J Nanomedicine; 2022; 17():4579-4598. PubMed ID: 36199476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal immune responses induced by transcutaneous vaccines.
    Lawson LB; Clements JD; Freytag LC
    Curr Top Microbiol Immunol; 2012; 354():19-37. PubMed ID: 22435116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of mucosal immunity through systemic immunization: Phantom or reality?
    Su F; Patel GB; Hu S; Chen W
    Hum Vaccin Immunother; 2016 Apr; 12(4):1070-9. PubMed ID: 26752023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.